ClinicalTrials.gg
CompletedNCT02411201Updated Mar 9, 2017Results posted

DOTAREM Pharmacokinetics and Safety Study in Pediatric Subjects Aged < 2 Years

A Phase 4 interventional study of DOTAREM in Magnetic Resonance Imaging, sponsored by Guerbet. Completed at 9 sites in 4 countries. Open to participants aged Up to 2 Years. Per ClinicalTrials.gov, last updated 2017-03-09.

Sponsored by Guerbet · Phase 4, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
Up to 2 Years
Sex
All
01

Study summary

The main purpose of the study is to evaluate the pharmacokinetics of DOTAREM® in the body of children aged less than 2 years thanks to several blood samples (3 ml in total) taken following the administration of DOTAREM®.

DOTAREM® is a contrast agent commonly used for enhancement of Magnetic Resonance Imaging (MRI) to potentially improve the quality of the images and help the diagnosis. Children aged less than 2 years scheduled to undergo routine gadolinium-enhanced MRI of any body region may take part in the study. In this case they will receive DOTAREM®, a solution injected at the standard dose of 0.2mL/kg (0.1 mmol/kg) of body weight.

02

Conditions studied

  • Magnetic Resonance Imaging
03

In context

Lead sponsor

Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 2 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric subject aged \<2 years (term newborn infants to toddlers 23 months of age inclusive). Term is defined as ≥37 weeks of amenorrhea
  • Subject is scheduled to undergo routine gadolinium-enhanced MRI of any body region (e.g. CNS, cardiac) at the dose of 0.1 mmol/kg BW (0.2 mL/kg BW)
  • Subject with normal renal function for its age, estimated calculated based on the Schwartz formula

Exclusion criteria

Exclusion Criteria:

  • Subject planned for intervention (e.g. surgery) between the screening visit and up to 24 hours after DOTAREM injection
  • Subject whose preceding or subsequent treatment to DOTAREM injection (e.g., blood loss or receiving blood, treatment with diuretics, etc...) would alter DOTAREM pharmacokinetics parameters
  • Subject with subsequent planned treatment after DOTAREM injection that would prevent obtaining the required blood samples (e.g., emergency surgery, etc...)
  • Subject with a history of a bleeding disorder
  • Subject with severe liver disease (Child's Pugh Classification B or greater or serum direct greater than 0.3 mg/dL, age adjusted)
  • Subject with electrolyte or fluid imbalance that presents undue risk
  • Subject undergoing a change in chemotherapy within 48 hours prior to and up to 24 hours after DOTAREM injection
  • Subject who received or will receive any other contrast agent within 72 hours prior to DOTAREM injection or up to 24 hours after DOTAREM injection
  • Subject with for MRI such as iron metal implants (e.g. aneurysm clips)
  • Subject with history of anaphylactoid or anaphylactic reaction to any allergen including drugs and contrast agents
  • Subject having participated within 30 days in a clinical study involving an drug or device
  • Subject planned to participate simultaneously to another clinical study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    DOTAREM

    Drug: DOTAREM

Interventions

  • Single intravenous injection of 0.1 mmol/kg body weight

    Also known as: gadoterate meglumine

06

What researchers measure

Primary outcomes

  1. Area Under the Curve of DOTAREM in Plasma

    Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Area under the curve was determined from typical and individual DOTAREM concentration-time profiles.

    Time frame: Blood samples were collected during 3 time windows: 15 min to 60 min, 2 hours to 4 hours and 6 hours to 8 hours post-injection

  2. Rate Constant of the Terminal Phase of DOTAREM

    Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Rate constant of the terminal phase was determined from typical and individual DOTAREM concentration-time profiles.

    Time frame: Blood samples were collected during 3 time windows: 15 min to 60 min, 2 hours to 4 hours and 6 hours to 8 hours post-injection

  3. Terminal Elimination Half-life of DOTAREM From Plasma

    Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Terminal elimination half-life was determined from typical and individual DOTAREM concentration-time profiles.

    Time frame: Blood samples were collected during 3 time windows: 15 min to 60 min, 2 hours to 4 hours and 6 hours to 8 hours post-injection

  4. Total Clearance of DOTAREM From Plasma

    Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Total clearance was determined from typical and individual DOTAREM concentration-time profiles.

    Time frame: Blood samples were collected during 3 time windows: 15 min to 60 min, 2 hours to 4 hours and 6 hours to 8 hours post-injection

  5. Volume of Distribution of DOTAREM at Steady State

    Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Volume of distribution at steady state was determined from typical and individual DOTAREM concentration-time profiles.

    Time frame: Blood samples were collected during 3 time windows: 15 min to 60 min, 2 hours to 4 hours and 6 hours to 8 hours post-injection

Secondary outcomes

  1. Simulated Plasma Concentration of DOTAREM

    Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method.

    Time frame: at 10 and 20 min post-injection

  2. MRI Lesion Visualization at Subject Level

    Lesion visualization was assessed on up to five most representative lesions per subject based on scoring of 3 co-endpoints: * border delineation (based on a 3-point scale where 1=none; 2=moderate and 3=clear and complete) * internal morphology (based on a 3-point scale where 1=poorly visible; 2=moderately visible and 3=sufficiently visible) * contrast enhancement (based on a 3-point scale where 1=none; 2=weak and 3=clear and bright) For each co-endpoint, a sum of scores was calculated at subject level as follows: sum of scores = score of the lesion 1 (+ score of the lesion 2 + score of the lesion 3 + score of the lesion 4 + score of the lesion 5, when applicable)

    Time frame: Pre-injection and post-injection (estimated between 5 and 20 minutes after injection)

07

Results

Posted Mar 9, 2017

Participant flow

A total of 51 children aged less than 2 years were recruited in 4 countries: Austria, France, Hungary and Poland.

Participant flow — Overall Study
MilestoneDOTAREM
Started51
Completed45
Not completed6
Withdrew: Adverse event2
Withdrew: Withdrawal by subject2
Withdrew: Age group completed2

Outcome measures

PrimaryArea Under the Curve of DOTAREM in Plasma

Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Area under the curve was determined from typical and individual DOTAREM concentration-time profiles.

Time frame:
Blood samples were collected during 3 time windows: 15 min to 60 min, 2 hours to 4 hours and 6 hours to 8 hours post-injection
Reported as:
Median · hour.µmol/L
Area Under the Curve of DOTAREM in Plasma
hour.µmol/LDOTAREM
Area Under the Curve of DOTAREM in Plasma1591.1 (981.43 to 2841)
PrimaryRate Constant of the Terminal Phase of DOTAREM

Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Rate constant of the terminal phase was determined from typical and individual DOTAREM concentration-time profiles.

Time frame:
Blood samples were collected during 3 time windows: 15 min to 60 min, 2 hours to 4 hours and 6 hours to 8 hours post-injection
Reported as:
Median · hour-1
Rate Constant of the Terminal Phase of DOTAREM
hour-1DOTAREM
Rate Constant of the Terminal Phase of DOTAREM0.5117 (0.2288 to 0.7824)
PrimaryTerminal Elimination Half-life of DOTAREM From Plasma

Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Terminal elimination half-life was determined from typical and individual DOTAREM concentration-time profiles.

Time frame:
Blood samples were collected during 3 time windows: 15 min to 60 min, 2 hours to 4 hours and 6 hours to 8 hours post-injection
Reported as:
Mean · hour
Terminal Elimination Half-life of DOTAREM From Plasma
hourDOTAREM
Terminal Elimination Half-life of DOTAREM From Plasma1.3545 (0.8859 to 3.0291)
PrimaryTotal Clearance of DOTAREM From Plasma

Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Total clearance was determined from typical and individual DOTAREM concentration-time profiles.

Time frame:
Blood samples were collected during 3 time windows: 15 min to 60 min, 2 hours to 4 hours and 6 hours to 8 hours post-injection
Reported as:
Mean · L/hour per kg
Total Clearance of DOTAREM From Plasma
L/hour per kgDOTAREM
Total Clearance of DOTAREM From Plasma0.0602 (0.0352 to 0.1019)
PrimaryVolume of Distribution of DOTAREM at Steady State

Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method. Volume of distribution at steady state was determined from typical and individual DOTAREM concentration-time profiles.

Time frame:
Blood samples were collected during 3 time windows: 15 min to 60 min, 2 hours to 4 hours and 6 hours to 8 hours post-injection
Reported as:
Mean · L/kg
Volume of Distribution of DOTAREM at Steady State
L/kgDOTAREM
Volume of Distribution of DOTAREM at Steady State0.0473 (0.0273 to 0.1597)
SecondarySimulated Plasma Concentration of DOTAREM

Pharmacokinetics interpretation was performed using a pharmacokinetic population modelling approach. DOTAREM concentrations in plasma were analyzed using a validated LC-MS/MS method.

Time frame:
at 10 and 20 min post-injection
Reported as:
Median · µmol/L
Simulated Plasma Concentration of DOTAREM
µmol/LDOTAREM
Simulated concentration at 10 min320.92 (45.223 to 2857)
Simulated concentration at 20 min275.67 (47.048 to 1565.1)
SecondaryMRI Lesion Visualization at Subject Level

Lesion visualization was assessed on up to five most representative lesions per subject based on scoring of 3 co-endpoints: * border delineation (based on a 3-point scale where 1=none; 2=moderate and 3=clear and complete) * internal morphology (based on a 3-point scale where 1=poorly visible; 2=moderately visible and 3=sufficiently visible) * contrast enhancement (based on a 3-point scale where 1=none; 2=weak and 3=clear and bright) For each co-endpoint, a sum of scores was calculated at subject level as follows: sum of scores = score of the lesion 1 (+ score of the lesion 2 + score of the lesion 3 + score of the lesion 4 + score of the lesion 5, when applicable)

Time frame:
Pre-injection and post-injection (estimated between 5 and 20 minutes after injection)
Reported as:
Mean · units on a scale
MRI Lesion Visualization at Subject Level
units on a scalePre-contrastPre- + Post-contrast
Sum of scores of lesion border delineation4.3 ± 3.75.1 ± 4.0
Sum of scores of internal morphology4.3 ± 3.95.2 ± 4.3
Sum of scores of contrast enhancement1.9 ± 1.55.0 ± 4.5

Adverse events

Collected over Adverse Events were collected from informed consent signature to the end of the study (7+/-1 day after DOTAREM administration). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DOTAREM—1/45 (2.2%)12/45 (26.7%)
Most frequent serious events
Most frequent serious events
EventDOTAREM
AnaemiaBlood and lymphatic system disorders1/45
PyrexiaGeneral disorders1/45
Upper respiratory tract infectionInfections and infestations1/45
Most frequent other events
Showing 10 of 18
Most frequent other events
EventDOTAREM
PyrexiaGeneral disorders5/45
LeukopeniaBlood and lymphatic system disorders2/45
Device difficult to useGeneral disorders1/45
FatigueGeneral disorders1/45
BronchitisInfections and infestations1/45
InfectionInfections and infestations1/45
NasopharyngitisInfections and infestations1/45
RhinitisInfections and infestations1/45
TonsillitisInfections and infestations1/45
Urinary tract infectionInfections and infestations1/45

Baseline characteristics

51 pediatric subjects were included in the study. 4 subjects could not be randomized due to consent withdrawal (n=1), adverse event (n=1) or other reason (n=2). 2 subjects did not receive DOTAREM due to consent withdrawal for 1 subject and adverse event for the second subject.

Age, Continuous
Age, Continuous(months)DOTAREM
Mean9.9 ± 7.4
Age, Customized
Age, Customized(Participants)DOTAREM
<1 month5
1 to 3 months9
>3 months to <24 months31
Sex: Female, Male
Sex: Female, Male(Participants)DOTAREM
Female23
Male22
Region of Enrollment
Region of Enrollment(participants)DOTAREM
Austria3
Hungary9
Poland29
France4
08

Study locations

9 sites
  • Landes-Frauen-und Kinderklinik Linz
    Linz, 4020, Austria
  • CHU
    Bordeaux, 33604, France
  • CHRU
    Lille, 59037, France
  • Hôpital de Hautepierre
    Strasbourg, 67098, France
  • Department of Molecular and Neurological Clinical and Research Center
    Budapest, 1083, Hungary
  • University of Debrecen Medical Center
    Debrecen, 4032, Hungary
  • Borsod-Abaúj-Zemplén University County Hospital
    Miskolc, 3526, Hungary
  • Uniwersytecki Szpital Dziecięcy w Lublinie
    Lublin, 20093, Poland
  • Instytut Pomnik -Centrum Zdrowia Dziecka
    Warszawa, 04730, Poland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2015
First posted
Apr 8, 2015
Start
Mar 2015
Primary completionActual
Oct 2015
CompletionActual
Oct 2015
Results first posted
Mar 9, 2017
Last update
Mar 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02411201
Lead sponsor
Guerbet
Responsible party
Sponsor
First posted
Apr 8, 2015
Start date
Mar 2015
Primary completion
Oct 2015
Completion
Oct 2015
Results posted
Mar 9, 2017
Last update
Mar 9, 2017

Study contacts

Project Manager
study director · Guerbet

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gadoterate meglumine

Start the discussion